Immune Pharmaceuticals Presentation Now Available for On-Demand Viewing


Company invites individual and institutional investors to login at

NEW YORK, Aug. 12, 2015 /CNW/ -- Immune Pharmaceuticals, Inc. ("Immune") (NASDAQ: IMNP), today announced that their August 6 presentation from Dr. Daniel Teper, CEO, is available for on-demand viewing at


Immune's presentation will be available 24/7 for 90 days. Investors and advisors may view shareholder materials from the "virtual trade booth" for the next three weeks.

Recent Company Highlights

  • Immune Pharmaceuticals secures Funding of up to $21.5 Million from Institutional Investors
  • Immune Pharmaceuticals Initiates Phase II Clinical Trials with Bertilimumab in Ulcerative Colitis and Bullous Pemphigoid
  • Immune Expands Immuno-Dermatology Development Portfolio with Topical Nano-Formulated Cyclosporine A
  • Immune Pharmaceuticals Signs License & Research Agreement for AmiKet™ Nano

Learn more about the event:

About Immune Pharmaceuticals 

Immune Pharmaceuticals Inc. applies a personalized approach to treating and, developing novel, highly-targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company's lead product candidate, Bertilimumab, is in clinical development for moderate to severe ulcerative colitis as well as for bullous pemphigoid, an orphan auto-immune dermatological condition. The Company recently expanded its portfolio in immuno-dermatology, topical nano-formulated Cyclosporine A (CsA) for the treatment of psoriasis and atopic dermatitis. Immune's pipeline also includes NanomAbs®, antibody nanoparticle conjugates, for the targeted delivery of chemotherapeutics. Other indications planned for development include Crohn's disease, severe asthma and NASH (liver disease).

For more information, visit Immune's website at 

About, created by BetterInvesting (NAIC) and PR Newswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.

Logo -

SOURCE Immune Pharmaceuticals, Inc.

For further information: Christine J. Petraglia, Director, Corporate Communications and Investor Relations, Immune Pharmaceuticals, Inc., +1.646.440.9310,; or, Bradley H. Smith, Director of Marketing, IR and Compliance Services, PR Newswire, +1.201.947.7157,,

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890